Meet us at 67th ASH Annual Meeting and Exposition
Meet our medical team to find out more about our clinical program and CAR-T therapies on December 6-9 in Orlando, Florida, USA
Meet us at 67th ASH Annual Meeting and Exposition
Meet our medical team to find out more about our clinical program and CAR-T therapies on December 6-9 in Orlando, Florida, USA
Join our oral presentation at ASH 2025
Join us during Oral Abstract Session 628: Aggressive Lymphomas for the presentation of the pivotal DALY 2-EU trial results
Abstract: Zamtocabtagene autoleucel, a tandem CD20-CD19 directed CAR-T cell therapy as second-line treatment for Relapsed/Refractory large B-cell lymphoma: primary analysis of the randomized, pivotal DALY 2-EU study
Where: Room OCCC - Tangerine Ballroom F3-4
When: Sunday, Dec 7, 2025, 5:00 p.m. - 5:15 p.m.
Session F: 628. Aggressive Lymphomas: Cellular Therapies: Novel Cellular Therapeutic Strategies for Aggressive Lymphomas
Latest resources from Miltenyi Biomedicine
View recent posters, presentations and press releases
Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (Zamto-Cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma - Interim Results from a Phase 2 Pivotal Study (DALY II USA)
Tandem Meetings – Transplantation & Cellular Therapy Meetings of ASTCT and CIBMTR | presentation slides
Interim Results from a Phase 2 Pivotal Study (DALY II USA) of Tandem CD20-CD19-Directed Non-Cryopreserved CAR-T Cells - Zamtocabtagene Autoleucel (zamto-cel) in Patients with Relapsed/Refractory Diffuse Large B Cell Lymphoma
ASH24 | presentation slides
Miltenyi Biomedicine will share positive interim results from DALY II USA at the American Society of Hematology (ASH) Annual Meeting
ASH 2024 | press release
Bispecific anti-CD20/19 CAR-T – zamtocabtagene autoleucel for relapsed/refractory DLCBL – interim analysis results of DALY-II-USA study
EHA2023 Hybrid Congress | poster information
Interim analysis of a Phase II study of administered fresh bispecific anti-CD20/anti-CD19 CAR-T cell therapy zamtocabtagene autoleucel (zamto-cel) for relapsed/refractory (R/R) DLBCL (DALY II USA, NCT04792489)
Tandem Meetings of ASTCT and CIBMTR 2023 I presentation slides
PHASE I TRIAL OF MB-CART2019.1 IN PATIENTS WITH RELAPSED OR REFRACTORY B CELL NON-HODGKIN LYMPHOMA
EHA 2022 | poster download
Characterization and T-Cell Repertoire of MB-CART2019.1 (Zamtocabtagene autoleucel) - Data from the Phase I Trial
ASH 2022 | presentation abstract
Healthcare Resource Utilization and Associated Costs of German Patients with Diffuse Large B-Cell Lymphoma (DLBCL)
ASH 2022 | presentation abstract
Survival Patients Newly Diagnosed with Diffuse Large B-Cell Lymphoma (DLBCL) - Real World Evidence from Germany
ASH 2022 | presentation abstract
We are looking forward to seeing you at #ASH25
We look forward to welcoming you to our booth (1271), where you will be able to speak to our medical team about our clinical program and open trials.
#ASH2025 will take place at the Orange County Convention Center in Orlando, Florida. You will find us at the Miltenyi Biomedicine booth 1271
Exhibition opening hours:
Saturday, 6 December, 11:00 a.m. - 5:00 p.m.
Sunday, 7 December, 10:00 a.m. - 5:00 p.m.
Monday, 8 December, 10:00 a.m. - 2:00 p.m.
